Published in JAMA Neurol on January 01, 2013
TREM2 variants in Alzheimer's disease. N Engl J Med (2012) 11.35
Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med (2012) 10.16
Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci (2014) 2.59
TREM2 is associated with the risk of Alzheimer's disease in Spanish population. Neurobiol Aging (2013) 2.19
TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell (2015) 2.15
Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci (2015) 1.94
A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep (2013) 1.92
TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med (2015) 1.88
TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener (2013) 1.83
The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimers Dement (2015) 1.66
Alzheimer's disease genetics: from the bench to the clinic. Neuron (2014) 1.65
TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol (2014) 1.63
Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease. Neurobiol Aging (2013) 1.53
Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. Sci Transl Med (2016) 1.44
Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry (2014) 1.42
Coding variants in TREM2 increase risk for Alzheimer's disease. Hum Mol Genet (2014) 1.36
Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and γ-secretase-dependent intramembranous cleavage. J Biol Chem (2013) 1.24
TREM2 and the neuroimmunology of Alzheimer's disease. Biochem Pharmacol (2013) 1.18
TREM2 is associated with increased risk for Alzheimer's disease in African Americans. Mol Neurodegener (2015) 1.05
USP18 lack in microglia causes destructive interferonopathy of the mouse brain. EMBO J (2015) 1.05
Novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family. Neurobiol Aging (2013) 1.04
Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). J Biol Chem (2015) 1.04
Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol (2016) 1.03
The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E. J Biol Chem (2015) 1.03
Genetics of Alzheimer's disease. Neurotherapeutics (2014) 1.02
Next generation sequencing techniques in neurological diseases: redefining clinical and molecular associations. Hum Mol Genet (2014) 1.02
sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med (2016) 0.97
TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci (2016) 0.97
Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Mol Neurodegener (2016) 0.96
TREM2 regulates microglial cell activation in response to demyelination in vivo. Acta Neuropathol (2015) 0.95
Review: The genetics of Alzheimer's disease; putting flesh on the bones. Neuropathol Appl Neurobiol (2014) 0.93
Neuroinflammation: Ways in Which the Immune System Affects the Brain. Neurotherapeutics (2015) 0.93
The innate immune system in Alzheimer's disease. Int J Cell Biol (2013) 0.92
Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease. Alzheimers Res Ther (2013) 0.91
TREM2 in CNS homeostasis and neurodegenerative disease. Mol Neurodegener (2015) 0.89
The triggering receptor expressed on myeloid cells 2: "TREM-ming" the inflammatory component associated with Alzheimer's disease. Oxid Med Cell Longev (2013) 0.89
R47H TREM2 variant increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia. Alzheimers Dement (2014) 0.89
R47H Variant of TREM2 Associated With Alzheimer Disease in a Large Late-Onset Family: Clinical, Genetic, and Neuropathological Study. JAMA Neurol (2015) 0.88
Homozygous TREM2 mutation in a family with atypical frontotemporal dementia. Neurobiol Aging (2014) 0.87
Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia. Front Aging Neurosci (2015) 0.87
The Evolution of Genetics: Alzheimer's and Parkinson's Diseases. Neuron (2016) 0.87
Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci Rep (2015) 0.86
The established and emerging roles of astrocytes and microglia in amyotrophic lateral sclerosis and frontotemporal dementia. Front Cell Neurosci (2015) 0.86
More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk. Neurobiol Aging (2015) 0.85
Nonsense mutation in PRNP associated with clinical Alzheimer's disease. Neurobiol Aging (2014) 0.84
Central nervous system myeloid cells as drug targets: current status and translational challenges. Nat Rev Drug Discov (2015) 0.83
The Triggering Receptor Expressed on Myeloid Cells 2: A Molecular Link of Neuroinflammation and Neurodegenerative Diseases. J Biol Chem (2015) 0.82
The role of peripheral immune cells in the CNS in steady state and disease. Nat Neurosci (2017) 0.82
The anti-inflammatory glycoprotein, CD200, restores neurogenesis and enhances amyloid phagocytosis in a mouse model of Alzheimer's disease. Neurobiol Aging (2015) 0.82
Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging. J Neuroinflammation (2015) 0.81
The Role of TREM2 in Alzheimer's Disease and Other Neurological Disorders. J Alzheimers Dis Parkinsonism (2014) 0.81
Rare TREM2 variants associated with Alzheimer's disease display reduced cell surface expression. Acta Neuropathol Commun (2016) 0.80
Differential modulation of TREM2 protein during postnatal brain development in mice. PLoS One (2013) 0.79
Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. Elife (2016) 0.79
Parkinsonism, movement disorders and genetics in frontotemporal dementia. Nat Rev Neurol (2016) 0.79
Frontobasal gray matter loss is associated with the TREM2 p.R47H variant. Neurobiol Aging (2014) 0.79
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. Alzheimers Res Ther (2016) 0.78
Microglia: Architects of the Developing Nervous System. Trends Cell Biol (2016) 0.78
TREM2, frontotemporal dementia-like disease, Nasu-Hakola disease, and Alzheimer dementia: a chicken and egg problem? JAMA Neurol (2013) 0.78
Soluble TREM2 induces inflammatory responses and enhances microglial survival. J Exp Med (2017) 0.78
Preparation, crystallization, and preliminary crystallographic analysis of wild-type and mutant human TREM-2 ectodomains linked to neurodegenerative and inflammatory diseases. Protein Expr Purif (2014) 0.77
Obesity and genomics: role of technology in unraveling the complex genetic architecture of obesity. Hum Genet (2015) 0.77
Alzheimer disease: TREM2 linked to late-onset AD. Nat Rev Neurol (2012) 0.77
Functional involvement of γ-secretase in signaling of the triggering receptor expressed on myeloid cells-2 (TREM2). J Neuroinflammation (2016) 0.76
Regulation of microglial survival and proliferation in health and diseases. Semin Immunol (2016) 0.76
Therapeutic and diagnostic challenges for frontotemporal dementia. Front Aging Neurosci (2014) 0.76
Genes associated with Alzheimer's disease: an overview and current status. Clin Interv Aging (2016) 0.76
Neuroinflammation - using big data to inform clinical practice. Nat Rev Neurol (2016) 0.75
Assessment of TREM2 rs75932628 association with Parkinson's disease and multiple system atrophy in a Chinese population. Neurol Sci (2015) 0.75
Early microgliosis precedes neuronal loss and behavioural impairment in mice with a frontotemporal dementia-causing CHMP2B mutation. Hum Mol Genet (2017) 0.75
Altered Neuroinflammation and Behavior after Traumatic Brain Injury in a Mouse Model of Alzheimer's Disease. J Neurotrauma (2015) 0.75
TREM2-ligand interactions in health and disease. J Mol Biol (2017) 0.75
The Birth of the Modern Era of Parkinson's Disease Genetics. J Parkinsons Dis (2017) 0.75
The Alzheimer's disease risk factors apolipoprotein E and TREM2 are linked in a receptor signaling pathway. J Neuroinflammation (2017) 0.75
Divergent Neuroinflammatory Regulation of Microglial TREM Expression and Involvement of NF-κB. Front Cell Neurosci (2017) 0.75
Mutation Frequency of the Major Frontotemporal Dementia Genes, MAPT, GRN and C9ORF72 in a Turkish Cohort of Dementia Patients. PLoS One (2016) 0.75
Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease. BMC Med Genomics (2016) 0.75
Multiple variants in families with amyotrophic lateral sclerosis and frontotemporal dementia related to C9orf72 repeat expansion: further observations on their oligogenic nature. J Neurol (2017) 0.75
Recent advances in the molecular genetics of frontotemporal lobar degeneration. Funct Neurol (2017) 0.75
TREM2 in Neurodegenerative Diseases. Mol Neurodegener (2017) 0.75
Neurodegeneration-associated mutant TREM2 proteins abortively cycle between the ER and ER-Golgi intermediate compartment. Mol Biol Cell (2017) 0.75
The Role of Microglia in Prion Diseases: A Paradigm of Functional Diversity. Front Aging Neurosci (2017) 0.75
CNS inflammation and neurodegeneration. J Clin Invest (2017) 0.75
The Sequence Alignment/Map format and SAMtools. Bioinformatics (2009) 232.39
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Exome sequencing identifies the cause of a mendelian disorder. Nat Genet (2009) 32.06
Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology (1998) 26.77
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 20.15
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron (2011) 18.73
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
A human genome diversity cell line panel. Science (2002) 14.11
Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med (2010) 13.57
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature (2006) 11.59
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90
Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature (2006) 9.31
Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol (2000) 5.37
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet (2011) 4.52
VPS35 mutations in Parkinson disease. Am J Hum Genet (2011) 4.16
Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet (2002) 4.06
TREMs in the immune system and beyond. Nat Rev Immunol (2003) 3.57
The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology (2005) 2.77
CNS manifestations of Nasu-Hakola disease: a frontal dementia with bone cysts. Neurology (2001) 2.27
Mutations in TREM2 lead to pure early-onset dementia without bone cysts. Hum Mutat (2008) 1.78
FancyGene: dynamic visualization of gene structures and protein domain architectures on genomic loci. Bioinformatics (2009) 1.67
Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy--PLOSL): a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects. Cell Mol Neurobiol (2004) 1.44
An Italian family affected by Nasu-Hakola disease with a novel genetic mutation in the TREM2 gene. J Neurol Neurosurg Psychiatry (2003) 1.22
Neuropsychological tests and functional nuclear neuroimaging provide evidence of subclinical impairment in Nasu-Hakola disease heterozygotes. Funct Neurol (2005) 1.12
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron (2011) 18.73
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
A survey of genetic human cortical gene expression. Nat Genet (2007) 12.04
TREM2 variants in Alzheimer's disease. N Engl J Med (2012) 11.35
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet (2011) 9.10
Genomewide association studies and human disease. N Engl J Med (2009) 9.05
Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol (2006) 7.32
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry (2007) 7.23
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
Automatic classification of MR scans in Alzheimer's disease. Brain (2008) 6.71
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66
Parkinson's disease. Lancet (2009) 6.60
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis (2006) 5.96
Toxic proteins in neurodegenerative disease. Science (2002) 5.82
A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet (2005) 5.81
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. Hum Mol Genet (2006) 5.50
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 5.18
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet (2008) 4.75
Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet (2008) 4.69
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain (2009) 4.01
Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol (2007) 3.93
Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am J Hum Genet (2012) 3.80
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet (2005) 3.63
Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol (2009) 3.62
Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol (2010) 3.61
Genetics of Parkinson's disease and parkinsonism. Ann Neurol (2006) 3.60
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Evolutionary toggling of the MAPT 17q21.31 inversion region. Nat Genet (2008) 3.42
Genome-wide analyses of exonic copy number variants in a family-based study point to novel autism susceptibility genes. PLoS Genet (2009) 3.42
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet (2011) 3.40
Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. PLoS Genet (2009) 3.38
Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet (2009) 3.35
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
Chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiol Aging (2011) 3.27
Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat Commun (2011) 3.23
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet (2004) 3.12
DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol (2008) 3.03
Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A (2005) 3.02
A genome-wide genotyping study in patients with ischaemic stroke: initial analysis and data release. Lancet Neurol (2007) 2.99
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med (2006) 2.93
Quality control parameters on a large dataset of regionally dissected human control brains for whole genome expression studies. J Neurochem (2011) 2.82
Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron (2002) 2.65
Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain (2012) 2.65
Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J (2003) 2.64
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Meta-analysis of genome-wide association data identifies two loci influencing age at menarche. Nat Genet (2009) 2.58
Repeat expansion in C9ORF72 in Alzheimer's disease. N Engl J Med (2012) 2.58
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet (2010) 2.51
Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol (2010) 2.48
ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord (2010) 2.47
Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord (2006) 2.47
Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry (2010) 2.44
The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis (2006) 2.42
β-Propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation. Brain (2013) 2.40
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
Antiamyloid therapy for Alzheimer's disease--are we on the right road? N Engl J Med (2014) 2.29
Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain (2012) 2.28
Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23
Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Hum Mol Genet (2010) 2.21
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol (2012) 2.20
Whole genome analyses suggest ischemic stroke and heart disease share an association with polymorphisms on chromosome 9p21. Stroke (2008) 2.19
A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain (2008) 2.13
Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain (2011) 2.13
Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nat Genet (2012) 2.12
Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans. PLoS Genet (2007) 2.09
Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet (2013) 2.09
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord (2006) 2.04
A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. Am J Hum Genet (2005) 2.04
Identical twins with Leucine rich repeat kinase type 2 mutations discordant for Parkinson's disease. Mov Disord (2012) 2.02